TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36859316

Group type: EXPERIMENTAL
Intervention: Nalmefene 0.25 µg/kg
Number of subjects: 520

Group type: COMPARATOR
Intervention: 0.9% NaCl solution (control)
Number of subjects: 520
Study: 36859391

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) defined as an apnea hypopnea index (AHI) ≥ 15 events/hour
Number of subjects: 1927

Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Prior stroke
Number of subjects: 1927
Study: 36859437

Group type: EXPERIMENTAL
Intervention: Intradialytic Resistance Training (IRT) for 12 weeks (EXG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no IRT) for 12 weeks (CNG)
Number of subjects: 90
Study: 36859467

Group type: EXPERIMENTAL
Intervention: Oral triheptanoin at a dose of 1 g/Kg/day, providing near 35% of total caloric intake.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of triheptanoin at 45% of daily caloric intake for each age group.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triheptanoin treatment.
Number of subjects: 6
Study: 36859514

Group type: EXPERIMENTAL
Intervention: Investigated inherited risk factors for thrombosis in 4 patients
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acquired risk factors
Number of subjects: 11
Study: 36859619

Group type: EXPERIMENTAL
Intervention: BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3)
Number of subjects: 6
Study: 36860093

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated adolescents and caregivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child's age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver education (Economic Hardship Index score)
Number of subjects: 0
Study: 36860268

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus pomalidomide and dexamethasone (EPd)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone (Pd)
Number of subjects: 117
Study: 36860319

Group type: EXPERIMENTAL
Intervention: Cetuximab-based treatment regimen
Number of subjects: 0
Study: 36860772

Group type: EXPERIMENTAL
Intervention: Bone bruise volume
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: International Knee Documentation Committee (IKDC-2000) score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ACL-Return to Sport after Injury (ACL-RSI) score
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Objective functional performance battery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Graft reinjury rate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Level of return to sport/activity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single Assessment Numeric Evaluation (SANE)
Number of subjects: 60
Study: 36861013

Group type: EXPERIMENTAL
Intervention: Arbaclofen extended-release 80 mg/day
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Arbaclofen extended-release
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 36861044

Group type: EXPERIMENTAL
Intervention: Plasma sTREM-1 and monocyte HLA-DR measured at D1/D2, D3/D4, and D6/D8
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Decreased mHLA-DR at D6/D8
Number of subjects: 116
Study: 36861085

Group type: EXPERIMENTAL
Intervention: Ribociclib + Aromatase Inhibitor (AI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abemaciclib + Aromatase Inhibitor (AI)
Number of subjects: 0
Study: 36861188

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg (single dose) administered using two pediatric formulations: 0.1 mg sprinkle capsule (age <28 days) and 0.4 mg/ml solution (age 28 days to <18 years); dose range 1.08-2.19 mg/mL.
Number of subjects: 0
Study: 36861269

Group type: EXPERIMENTAL
Intervention: Vascularized bone graft
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-vascularized iliac crest graft
Number of subjects: 45
Study: 36861346

Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) therapy, administered as long-term routine twice weekly prophylaxis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) therapy.
Number of subjects: 0
Study: 36861433

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg and Reboxetine 6 mg (oxy-reb)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 36861447

Group type: EXPERIMENTAL
Intervention: Platinum-containing chemotherapy
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Platinum-free chemotherapy
Number of subjects: 189
Study: 36861945

Group type: EXPERIMENTAL
Intervention: Active tDCS combined with cognitive training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham tDCS combined with cognitive training
Number of subjects: 38
Study: 36861976

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg by mouth twice daily on day 1 followed by 200 mg by mouth twice daily on days 2 to 5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oral placebo with the same schedule)
Number of subjects: 0
Study: 36862168

Group type: EXPERIMENTAL
Intervention: D-VCd
Number of subjects: 60

Group type: COMPARATOR
Intervention: VCd
Number of subjects: 60
Study: 36862181

Group type: EXPERIMENTAL
Intervention: Location on the foot (distal location)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proximal locations (thigh, leg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distal melanomas (mainly on the foot)
Number of subjects: 0
Study: 36862314

Group type: EXPERIMENTAL
Intervention: Connecting and Reflecting Experience (CARE) program
Number of subjects: 32
Study: 36862361

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 50
Study: 36862461

Group type: EXPERIMENTAL
Intervention: Scheduled SMS text messaging (SM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Social Support (SS) with SMS text messaging reminders
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine antenatal care (ANC; control)
Number of subjects: 120
Study: 36862463

Group type: EXPERIMENTAL
Intervention: Trust/respect plus symptom feedback
Number of subjects: 185

Group type: COMPARATOR
Intervention: Symptom feedback only
Number of subjects: 185
Study: 36862472

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy (CBCT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Topical lidocaine
Number of subjects: 108
Study: 36862574

Group type: EXPERIMENTAL
Intervention: Emotion-oriented coping
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dysfunctional coping
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Problem-focused strategies
Number of subjects: 150
Study: 36862648

Group type: EXPERIMENTAL
Intervention: Peer-led diabetes self-management education and long-term ongoing support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes self-management education (control)
Number of subjects: 0
Study: 36862681

Group type: COMPARATOR
Intervention: Female group (n = 1679)
Number of subjects: 6613

Group type: COMPARATOR
Intervention: Male group (n = 4934)
Number of subjects: 6613
Study: 36862693

Group type: EXPERIMENTAL
Intervention: In-phase bilateral exercises of the upper limbs (30-60 minutes/session, 3 sessions/week for 12 weeks)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: In-phase bilateral exercises
Number of subjects: 5
Study: 36862754

Group type: EXPERIMENTAL
Intervention: Accountable Care (AC) - enhanced monitoring and supervision
Number of subjects: 815

Group type: COMPARATOR
Intervention: Standard Care (SC) - existing supervisors
Number of subjects: 815
Study: 36862966

Group type: EXPERIMENTAL
Intervention: Liquid biopsy (FoundationOne Liquid CDx)
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Incidental findings of high-risk CH through liquid biopsy
Number of subjects: 1416
Study: 36862975

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 36
Study: 36863094

Group type: EXPERIMENTAL
Intervention: BMS-986156 + nivolumab
Number of subjects: 292

Group type: COMPARATOR
Intervention: BMS-986156
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: BMS-986156 ± nivolumab
Number of subjects: 292
Study: 36863106

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loudness dependence of auditory evoked potential (LDAEP)
Number of subjects: 0
Study: 36863287

Group type: EXPERIMENTAL
Intervention: Point-of-care HCV RNA testing, linkage to nursing care, and peer-supported engagement/delivery of treatment
Number of subjects: 101
Study: 36863292

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 80
Study: 36863386

Group type: EXPERIMENTAL
Intervention: 1-2 g of ferric carboxymaltose intravenously
Number of subjects: 202

Group type: COMPARATOR
Intervention: Three tablets of 200 mg of oral ferrous fumarate daily
Number of subjects: 202
Study: 36863390

Group type: EXPERIMENTAL
Intervention: 6-food elimination diet (6FED)
Number of subjects: 129

Group type: COMPARATOR
Intervention: 1-food elimination diet (1FED)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 6-food elimination diet (6FED) after 1FED non-responders
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Swallowed topical fluticasone propionate 880 μg twice per day after 6FED non-responders
Number of subjects: 129
Study: 36863410

Group type: EXPERIMENTAL
Intervention: Nociception Level (NOL) monitoring with sevoflurane and alfentanil (10 µg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nociception Level (NOL) monitoring
Number of subjects: 30
Study: 36863414

Group type: EXPERIMENTAL
Intervention: Internet-delivered parent training (iComet)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Group-delivered parent training (gComet)
Number of subjects: 161
Study: 36863645

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Normotensive pregnancy (Control)
Number of subjects: 1563
Study: 36863737

Group type: EXPERIMENTAL
Intervention: User-operated Audiometry (UAud)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Traditional audiometry
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: User-operated ACT test
Number of subjects: 250
Study: 36863739

Group type: EXPERIMENTAL
Intervention: Active whole-house UV device
Number of subjects: 908

Group type: COMPARATOR
Intervention: Sham (inactive UV device)
Number of subjects: 908
Study: 36863864

Group type: EXPERIMENTAL
Intervention: UC plus motivational interviewing (MI)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: UC plus a stratified vocational advice intervention (SVAI)
Number of subjects: 514

Group type: COMPARATOR
Intervention: usual case management (UC)
Number of subjects: 514
Study: 36863860

Group type: EXPERIMENTAL
Intervention: Therapists' first impression of treatment motivation
Number of subjects: 154
Study: 36863897

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of γδ T lymphocytes from haploidentical donors after lymphodepletion regimen
Number of subjects: 0
Study: 36864377

Group type: EXPERIMENTAL
Intervention: Mobile health technology-based follow-up programme with monthly individualized digital conversations with a PT and activity tracker; additional digital follow-up from a nutritional specialist for those at nutritional risk.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 100
Study: 36864394

Group type: EXPERIMENTAL
Intervention: Participants
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 1296
Study: 36864520

Group type: EXPERIMENTAL
Intervention: Pre-hospital trauma feasibility study
Number of subjects: 23
Study: 36864569

Group type: EXPERIMENTAL
Intervention: Washed microbiota transplantation (WMT)
Number of subjects: 259
Study: 36864622

Group type: EXPERIMENTAL
Intervention: RO5459072 (100 mg twice daily; 200 mg per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 36864635

Group type: EXPERIMENTAL
Intervention: Text messaging intervention added to ongoing social and behavioural change (SBC) interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing social and behavioural change (SBC) interventions without text messaging
Number of subjects: 0
Study: 36864699

Group type: EXPERIMENTAL
Intervention: Dual ovarian stimulation (duostim)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Two consecutive antagonist cycles (control)
Number of subjects: 88
Study: 36864701

Group type: EXPERIMENTAL
Intervention: Non-alcoholic fatty liver disease fibrosis score (NFS)
Number of subjects: 3212

Group type: EXPERIMENTAL
Intervention: BARD score
Number of subjects: 3212

Group type: EXPERIMENTAL
Intervention: AST/ALT ratio
Number of subjects: 3212

Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI) scores
Number of subjects: 3212

Group type: EXPERIMENTAL
Intervention: NFS
Number of subjects: 3212
Study: 36864705

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with a1-glucosidase alfa
Number of subjects: 6
Study: 36864830

Group type: EXPERIMENTAL
Intervention: Early AMD
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Intermediate AMD
Number of subjects: 434

Group type: COMPARATOR
Intervention: Normal
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Plasma L and Z
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: MPOV
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Correlation of MPOV with plasma L and Z
Number of subjects: 434
Study: 36864892

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 919

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 919
Study: 36864979

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg twice daily
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 36864985

Group type: EXPERIMENTAL
Intervention: ACBMNCs infusion
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 36865012

Group type: EXPERIMENTAL
Intervention: Patients with newly diagnosed CLI
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Patients without CLI
Number of subjects: 1136
Study: 36865055

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 36865121

Group type: EXPERIMENTAL
Intervention: EM Talk communication skills training (4-hour session with role-plays and active learning)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Post-intervention survey reflections
Number of subjects: 879
Study: 36865133

Group type: EXPERIMENTAL
Intervention: CG-806
Number of subjects: 0
Study: 36865151

Group type: EXPERIMENTAL
Intervention: REDCap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36865179

Group type: EXPERIMENTAL
Intervention: Therapists' care of mental health clients, including their wellbeing and experiences in treatment.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Integrated research and practice within the Mekong Project.
Number of subjects: 150
Study: 36865245

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention targeting distress and anxiety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36865252

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment to goal < 120 mm Hg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Standard treatment to goal < 140 mm Hg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 610
Study: 36865545

Group type: EXPERIMENTAL
Intervention: NK cell-based adoptive immunotherapy from HLA-haploidentical donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard methodology based on frequency of NK cell clones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative approach of phenotypic identification of NK cells
Number of subjects: 0
Study: 36865634

Group type: EXPERIMENTAL
Intervention: STEADY-PD III
Number of subjects: 998

Group type: COMPARATOR
Intervention: SURE-PD3
Number of subjects: 998
Study: 36865667

Group type: EXPERIMENTAL
Intervention: 2.5% diclofenac long duration sonophoresis (LDS) daily for 4 weeks
Number of subjects: 135
Study: 36865870

Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Microneedling with topical glutathione
Number of subjects: 31
Study: 36866155

Group type: COMPARATOR
Intervention: Retinal arterial and venous vessels in patients with POAG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuronal activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic vasoconstriction
Number of subjects: 0
Study: 36866389

Group type: EXPERIMENTAL
Intervention: Pegbelfermin
Number of subjects: 0
Study: 36866412

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 352
Study: 36866469

Group type: EXPERIMENTAL
Intervention: myo-inositol, probiotics, and additional micronutrients
Number of subjects: 1729
Study: 36866471

Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention promoting diet, exercise, and self-monitoring of obesity-related behaviours for 9 months
Number of subjects: 30529

Group type: COMPARATOR
Intervention: Control group with no promotion
Number of subjects: 30529

Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention
Number of subjects: 30529
Study: 36866658

Group type: EXPERIMENTAL
Intervention: Combination therapy (simultaneous use of SCS that does and does not produce tingling sensation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (only SCS therapy producing tingling sensation)
Number of subjects: 0
Study: 36866660

Group type: EXPERIMENTAL
Intervention: High PCAT attenuation group (n=244)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Low PCAT attenuation group (n=230)
Number of subjects: 474
Study: 36866835

Group type: EXPERIMENTAL
Intervention: Anxiety group (n=25)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-anxiety group (n=29)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 54
Study: 36866838

Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg once weekly for 4 weeks followed by every 2 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 2 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 4 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cemiplimab-containing arms (Isa + CemiQ2W and Isa + CemiQ4W)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival
Number of subjects: 106
Study: 36866852

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (from PREVENT trial)
Number of subjects: 58
Study: 36866921

Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 36867173

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Bupropion augmentation
Number of subjects: 619

Group type: COMPARATOR
Intervention: Switch to bupropion
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 619

Group type: COMPARATOR
Intervention: Switch to nortriptyline
Number of subjects: 619
Study: 36867455

Group type: EXPERIMENTAL
Intervention: Woebot for Adolescents (W-GenZD)
Number of subjects: 133

Group type: COMPARATOR
Intervention: telehealth-delivered CBT-based skills group (CBT-group)
Number of subjects: 133
Study: 36867504

Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 5 mg apixaban
Number of subjects: 181
Study: 36867756

Group type: EXPERIMENTAL
Intervention: Novel targets and models with complex multiscale interaction of data from different sources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-specific conditions and outcomes
Number of subjects: 0
Study: 36867758

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant interferon gamma
Number of subjects: 0
Study: 36867910

Group type: EXPERIMENTAL
Intervention: Low glutamate diet (LGD)
Number of subjects: 33
Study: 36868179

Group type: EXPERIMENTAL
Intervention: PK-guided pembrolizumab administration
Number of subjects: 33

Group type: COMPARATOR
Intervention: History-controlled cohort (pembrolizumab 200 mg 3-weekly for more than four cycles)
Number of subjects: 33
Study: 36868252

Group type: EXPERIMENTAL
Intervention: Nivolumab induction treatment (240 mg every 2 weeks for 4 doses)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab boost (1 mg/kg plus 3 mg/kg every 3 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nivolumab maintenance treatment
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nivolumab induction treatment
Number of subjects: 83
Study: 36868261

Group type: EXPERIMENTAL
Intervention: Garadacimab (400 mg loading dose followed by 200 mg monthly)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (volume-matched)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Garadacimab
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 36868377

Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 36868525

Group type: EXPERIMENTAL
Intervention: Institutional review of iPET response assessment
Number of subjects: 573

Group type: COMPARATOR
Intervention: Central review of iPET response assessment
Number of subjects: 573
Study: 36868587

Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation (NHFOV)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 340
Study: 36868591

Group type: EXPERIMENTAL
Intervention: Intensive cancer treatment and follow-up regimens
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Presence of a caregiver
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Health service configuration
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cancer diagnosis
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Treatment burden
Number of subjects: 35
Study: 36868590

Group type: EXPERIMENTAL
Intervention: Zero Suicide-Usual Care plus ASSIP
Number of subjects: 400

Group type: COMPARATOR
Intervention: Zero Suicide-Usual Care
Number of subjects: 400